Current Report Filing (8-k)
January 09 2023 - 08:04AM
Edgar (US Regulatory)
false 0001673772 0001673772 2023-01-09
2023-01-09
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 9,
2023
RAPT Therapeutics, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
|
Delaware |
|
001-38997 |
|
47-3313701 |
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
561 Eccles Avenue |
|
|
|
South San Francisco,
California |
|
94080 |
|
(Address of Principal Executive
Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: (650)
489-9000
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
|
Common Stock, $0.0001 par value per share |
|
RAPT |
|
The
NASDAQ Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§ 240.12b-2 of
this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
RAPT Therapeutics, Inc. (the “Company”) is filing the investor
presentation slides (the “Corporate Presentation”) attached as
Exhibit 99.1 to this Current Report on Form 8-K, which the Company may use from
time to time in conversations with investors and analysts.
| Item 9.01 |
Financial Statements and Exhibits.
|
(d) Exhibits
|
|
|
|
Exhibit
Number
|
|
Exhibit Description
|
|
|
| 99.1 |
|
Corporate Presentation. |
|
|
| 104 |
|
Cover Page Interactive Data File
(embedded within the Inline XBRL document) |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
RAPT Therapeutics, Inc. |
|
|
|
|
| Date: January 9, 2023 |
|
|
|
By: |
|
/s/ Rodney Young
|
|
|
|
|
|
|
Rodney Young |
|
|
|
|
|
|
Chief Financial Officer |
3
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Feb 2023 to Mar 2023
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Mar 2022 to Mar 2023
